Tag

Nandini Piramal

2 articles

Piramal Pharma Q4 Revenue Flat, FY26 PAT at -₹326Cr

Piramal Pharma reported flat Q4 revenue of ₹2,752Cr, with a full-year decline of 3% to ₹8,869Cr, impacted by CDMO destocking and soft ex-US anesthesia sales. The company recorded a full-year net loss

Piramal Pharma Q4 Net Profit Dips 5.6% YoY

• Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, reporting FY net profit of ₹700.01 crore. • Reappointed four directors including Executive Ch